NEW YORK (GenomeWeb) — SkylineDx, a Dutch molecular diagnostics company, has developed a new algorithm that can be used to predict the optimal treatment for patients with multiple myeloma.

The new computational tool, called TOPSPIN, complements the company's MMprofiler test, which stratifies multiple myeloma patients based on their microarray gene expression profile.

Using that information, clinicians can decide on a course of treatment according to their patient's genetic subtype.